Current research predominantly focuses on adolescents aged 12 years and older; however, investigating the use of GLP-1 agonists in younger children (e.g., ages 6–11) with obesity might substantially expand the range of these therapies. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.